Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 25 full-time employees. The company went IPO on 2014-11-18. The firm is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
Follow-Up Questions
Who is the CEO of Lunai Bioworks Inc?
Mr. David Weinstein is the Chief Executive Officer of Lunai Bioworks Inc, joining the firm since 2024.
What is the price performance of RENB stock?
The current price of RENB is $0.1671, it has increased 3.33% in the last trading day.
What are the primary business themes or industries for Lunai Bioworks Inc?
Lunai Bioworks Inc belongs to Biotechnology industry and the sector is Health Care
